All Posts By

courtney cruickshank

Perspectives on Managing Moderate-to-Severe Atopic Dermatitis

By Podcast

The Ps of Lichen Planus got nothing on this alliteration filled podcast that was purposefully positioned to perfect your practice prowess to punish the pruritus and picking of AD. Join host Dr. Adam Friedman in part four of five of this Atopic Dermatitis dedicated series as he parties with and picks the brains of dermatology powerhouses Dr.s April Armstrong and Lawrence Eichenfield on pursuing a practical and powerful process to partner with patients of all ages and partake in a long standing management strategy. Please do not push this one off – I promise it is educational perfection. (That’s 24 Ps!)

Upon completion of this podcast participants should be able to:

  • Discuss management strategies for patients with moderate-to-severe atopic dermatitis
  • Identify common co-morbidities of atopic dermatitis and strategies for optimal patient care

This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.

Disclosures
April W. Armstrong, MD, MPH – No disclosures.

Lawrence F. Eichenfield, MD – Grant/Research Support: Abbvie, Pfizer, Regeneron, Sanofi-Genzyme, Ortho Derm, Verrica. Consultant: Almirall, Arcutis, Asana, Dermavant, Dermira, Forte, Galderma, Incyte, Leo Pharma, Lilly, Novartis, OrthoDerm. Speakers’ Bureau: Pfizer, Regeneron, Sanofi-Genzyme.

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

Oral Antibiotics for Acne: Basic Concepts & Practical Considerations

By Podcast

Antibiotic use for inflammatory skin diseases is a staple in dermatology. Like milk is the answer to a chunky peanut butter sandwich (just go with me on this), so too have tetracycline antibiotics been married to the management of Acne Vulgaris. And just as that delicious combo comes at a fattening cost, the overuse and abuse of antibiotics has an impressive and significant impact both on the risk for antimicrobial resistance and gut/cutaneous dysbiosis. To get to the piloseabeous unit of the matter, JDD Podcast host Dr. Adam Friedman picks the brains of AAA experts Dr. Emmy Graber and Dr. Mahmoud Ghannoum to provide a true bench to bedside review of the issues at hand. Pop in to learn how to interpret minimum inhibitory concentrations (MIC), understand newly identified information on dysbiosis (including impaired microbiota), and appreciate the implications of indiscriminate use of broad-spectrum antibiotics in acne therapy including the clinical consequence of antibiotic resistance and benefits of narrow-spectrum agents.

Upon completion of this podcast participants should be able to:

  • Describe the differences between antibiotic types and their use in acne therapy
  • Discuss interpretation and measurement of MIC, resistance and dysbiosis
  • Summarize the clinical implications of antibiotic resistance
  • Summarize the clinical implications of dysbiosis

This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.

Disclosures

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

Mahmoud Ghannoum, PhD – Grant/Research: Almirall. Consultant: Almirall.

Emmy M. Graber, MD, MBA – Grant/Research: Ortho Dermatologics. Consultant: Almirall, Digital Diagnostics, Sebacia, SolGel. Speakers’ Bureau: Almirall.

Rocking the Red: A Rosacea Research and Real World Roundup

By Podcast

Rosacea is a complex, chronic inflammatory skin disease that is certainly not rockin for those who suffer with it. The pathophysiology is a smorgasbord of barrier dysfunction, reduced antioxidant capacity, inappropriate immune response, dysbiosis, and neurovascular dysregulation just to name a few. Much of what we know about this biological mess and translational understanding of our therapies comes from the legendary Dr. Richard Gallo, Distinguished Professor and Founding Chairman of the Department of Dermatology at the University of California, San Diego. Join host Dr. Adam Friedman as he readily runs through the bench to bedside gamut of rosacea. What are the major pathophysiologic pathways we should all know about? If we are to follow the data, how does out armament of FDA approved therapeutics fit in? So glad you asked! Re(a)dy, set, press play.

This podcast is supported by an independent medical education grant provided by Galderma.

Insights On the Pediatric, Adolescent & Adult AD Patient

By Podcast

You can’t truly understand someone until you walk a mile in their shoes. This is true to so many aspects of daily life, especially when it comes to chronic, relapsing, relentless medical issues. Enter the poster child: Atopic Dermatitis (AD). This exceedingly common chronic inflammatory disease is unavoidable in practice, and to best manage/partner with the millions of patients out there, it is on us to view/appreciate this condition beyond the practitioner lens. In this 3rd episode of a 5 part podcast series, host Dr. Adam Friedman is joined by Dr. Lindsey Finklea, a practicing dermatologist and parent/caregiver of a child with severe AD, and Dr. Peter Lio, podcast veteran and AD focused Derm extraordinaire, to discuss the issues affecting patient-family/patient-caregiver interactions and offer clinical pearls for effective management strategies to best assist the needs of parents, families and caregivers for patients with the AD.

This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.

Upon completion of this podcast, learners should be able to:

  • Cite the unique clinical implications of atopic dermatitis specific to the pediatric, adolescent and adult AD patient
  • Recognize the impact of AD on the patient-family and patient-caregiver dynamic

Disclosures

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

Peter Lio, MD – Advisory Board: Altus Labs, Arbonne, Bodewell, Dermavant Sciences, DermTap, Inc., DermVeda, gpower, inc., IntraDerm Pharmaceuticals, Johnson & Johnson Consumer Products Company, Menlo Therapeutics, Micreos Human Health B.V., Modernizing Medicine, National Eczema Association, Realm Therapeutics, Regeneron, Sanofi US Services, Syncere Skin Systems, UCB, Verrica Pharmaceuticals Inc, YobeeCare Inc. Board of Directors: National Eczema Association. Consultant: AbbVie, Amyris, Inc., Burt’s Bees, Dermira, Eli Lilly and Company, Exeltis, Franklin BioScience, Kiniksa Pharmaceuticals, Ltd., L’Oreal USA Inc., LEO Laboratories Ltd (LEO Pharma), Odeza LLC, Theraplex, TopMD, Unilever. Investigator: AbbVie, AOBiome, LLC, La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis, National Eczema Association, Regeneron. Speaker: Galderma USA, La Roche-Posay Laboratorie Pharmaceutique, Pfizer Inc., Pierre Fabre Dermatologie, Regeneron. Stockholder: LearnHealth/LearnSkin, Medable, Modernizing Medicine. Royalties: Theraplex.

Lindsay Finklea, MD – No relevant disclosures.

New Developments in Tetracycline-class Antibiotics

By Podcast
Tetracycline antibiotics are like the Snickers of dermatology. Instead of “Hungry? Grab a Snickers,” “Acne? Grab a tetracycline…” for months even though this goes against clinical guidelines and concerns regarding antimicrobial resistance (woof, thats a mouthful for a slogan). Like a Snickers, they fulfill a need, they’re good for a whole lot, but too much, not so good. We have seen some evolution in maximizing the clinical benefits of our therapeutic Snickers, such as subantimicrobial dosing, but more innovation is needed to get the most anti-inflammatory bang for our buck. Enter the concept of narrow spectrum antibiotics and sarecycline. Join host Dr. Adam Friedman on an investigative journey detailing how antibiotic structure and function can meet to yield novel properties with Dr. Chris Bunick, Associate Professor of Dermatology at Yale School of Medicine and captain of crystallography and cryo-electron microscopy. Hear first hand how a simple idea morphed into a groundbreaking program. Complete your understanding of how antibiotics can be anti-inflammatory. Love the new narrow spectrum lexicon (or try at least).
This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.
Upon completion of this podcast, learners should be able to:
  • Summarize the mechanism of action of tetracycline antibiotics and their role in acne
  • Define narrow spectrum antibiotic, and understand the clinical translation.
Disclosures
Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
Christopher Bunick, MD, PhD – Grant/Research: Almirall, Consultant: Almirall, Speakers’ Bureau: Almirall

Current Understanding of the Pathophysiology, Etiology, Prevalence & Burden of AD

By Podcast
In part 2 of this 5 part podcast homage to Atopic Dermatitis, JDD Podcast host Dr. Adam Friedman is joined by the dynamic dermatitis duo Dr. Anna De Benedetto, Associate Professor of Dermatology at the University of Florida, and Dr. Eric Simpson, Professor of Dermatology at the School of Medicine at Oregon Health & Science University, to dissect established and emerging pathophysiologic details of this dastardly dermatitis. Dig in to determine best evidence based management practices to dampen the long standing burden of disease. Discover delightful discourse between three dedicated AD investigators/caregivers. Do listen, don’t scratch.
This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.
Upon completion of this podcast, learners should be able to:
  • Summarize recent scientific understanding of the pathophysiology, etiology and prevalence of atopic dermatitis in patients of all age groups
  • Recognize the implications of long-term treatment options on effective patient outcomes.

Treating the AD Patient During COVID-19

By Podcast

Atopic dermatitis is a relentless, recurring, unreasonable, often recalcitrant inflammatory skin disease that impacts millions of children and adults in the United States alone and requires a tailored treatment plan and ongoing follow up. Now add a global pandemic to the mix – awesome. Join podcast host Dr Adam Friedman and atopic dermatitis antagonist Dr. Peter Lio as they discuss practical approaches to managing atopic dermatitis in the era of COVID-19. Telemedicine, topicals, and tons of systemic talk!

This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.
Upon completion of this podcast, learners should be able to:
  • Formulate AD treatment plans that may decrease susceptibility and spread of viral infections, including COVID-19
  • Identify new and emerging therapeutic considerations for managing atopic dermatitis during the current COVID-19 pandemic

Understanding and Changing Patient Behavior and Minimizing Risk of UV Damage

By Podcast

Episode 2 of a 2-Part Series: “Sun Protection: A Review of Current Interventions and Barriers to Changing Patient Attitude and Behavior”

Why is is that we tend to do things we know are bad for us? Candy, alcohol, Tinder…the list goes on. What about not following practices that have a library of evidence supporting their use, like sunscreen and photo-protection? To better understand this conundrum JDD Podcast host Dr. Adam Friedman recruited mental health guru Dr. Sherry Pagoto, Professor in the Department of Allied Health Sciences at the University of Connecticut and Director of the UConn Center for mHealth and Social Media, to dive deep into human behavior and how this relates to medical compliance. Find a couch to lie down on as you digest the litany of psychosocial pearls Dr. Pagoto shares, rounded out by some evidenced based guidance on using social media to engage a broader audience. #dontmissthispodcast

A CME exam is available for this podcast.

This enduring continuing education activity is supported by an independent medical education grant provided by Johnson & Johnson Consumer Inc. Participants who earn a minimum, passing grade of 70% would be eligible to receive up to 0.5 credit hours AMA PRA Category 1™ and ANCC credit per podcast. A total of 1 hour for this two-part Sun Protection series.

Learning Objectives:

Upon completion of this enduring, internet-based series of ontinuing education activities,  participants should be able to:

  • Develop strategies leading to effective clinician-patient dialogues to better motivate patients to integrate regular use of sunscreens in their skin care regimen

Disclosures:

Adam Friedman, MD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speaker’s Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

Sherry Pagoto, PhD – Consultant: Neutrogena/Johnson & Johnson.

The Science of Sun Protection

By Podcast

Episode 1 of a 2-Part Series: “Sun Protection: A Review of Current Interventions and Barriers to Changing Patient Attitude and Behavior”

Photoprotection works, plain and simple. Yet all too often we must defend good science, dispel unfounded myths, and offer our first born children to get our patients to utilize sunscreen the right way when this behavior directly and primarily benefits them. Why is this and how do we airdrop knowledge in a meaningful way? In part one of this bonus two part podcast series dedicated to the science and psychology of sunscreen use, AAD Vice President Elect Neal Bhatia, MD joins host Adam Friedman, MD to slather on some practical approaches to communicating sunscreen science and real world use.

A CME exam is available for this podcast.

This enduring continuing education activity is supported by an independent medical education grant provided by Johnson & Johnson Consumer Inc. Participants who earn a minimum, passing grade of 70% would be eligible to receive up to 0.5 credit hours AMA PRA Category 1™ and ANCC credit per podcast. A total of 1 hour for this two-part Sun Protection series.

Learning Objectives:
Upon completion of this enduring, internet-based series of continuing education activities, participants should be able to:

  • Differentiate features, benefits and limits of chemical and physical sunblocking products
  • Discuss the role of product formulation, delivery vehicle and patient type when recommending sun protection strategies
  • Review multifunctional approaches to photoprotection including use of sunscreen-containing moisturizers and other skin care products
  • Develop strategies leading to effective clinician-patient dialogues to better motivate patients to integrate regular use of sunscreens in their skin care regimen

Disclosures:
Adam Friedman, MD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speaker’s Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

Neal Bhatia, MD – Affiliations with Abbvie, Aclaris, Almirall, Biofrontera, BMS, BiopharmX, Dermira, Encore, EPI Health, Ferndale, Foamix, Galderma, Intraderm, ISDIN, J&J, LaRoche- Posay, Leo, Lilly, Mayne, Menlo, Novartis, Ortho, Pfizer, Pierre-Fabre, Regeneron, Sanofi, SkinFix, Soligenix, SunPharma, Vidac, and Vyome.

Support the (On)cause: A Practical Review of Supportive Oncodermatology

By Podcast

Cancer sucks, plain and simple. What is often overlooked is that the life saving/altering therapies often come with substantial baggage adding to this proclamation with skin, hair, and nail adverse events significantly impacting quality of life and even treatment course. Enter supportive oncodermatology, and along with it the mastermind behind this rapidly emerging field, Dr. Mario Lacouture, Professor and Director of the Oncodermatology Program in the Dermatology Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center in New York City. Dr. Lacatoure joins podcast host Dr. Adam Friedman to discuss the array of cutaneous clusters that not only can, but are almost expected to occur during cancer therapy. Learn how even simple OTC products can contribute to both ameliorating and even preventing some of these sequelae. Understand how you (yeah, I’m talkin’ to you) can make an extraordinary impact in these patients’ lives. Tune in to this podcast to support your supportive oncoderm fund of knowledge.

This podcast was supported by Johnson & Johnson Consumer Inc.

Upcoming Related Supplement:

The Biological Impact of Oats: Eczema and Beyond
Blair Allais MD and Adam Friedman MD FAAD
Department of Dermatology, George Washington School of Medicine and Health Sciences, Washington, DC
October 2020 | Volume 19 | Issue 10 | Supplement| Copyright © October 2020

Best Practices & Pearls Safely Reopening Derm Practices

By Podcast

The COVID-19 pandemic has affected dermatology practices across the country and around the world. In the face of a change that no one was really prepared for, Dr. Jeffrey S. Dover, in partnership with the JDD, invited a panel of dermatology Key Opinion Leaders to share their experience via video as they reopen their practices. We have gathered the audio from all of these videos and assembled them into an easy to listen to podcast filled with practical pearls and best practices from Drs. Jeffrey Dover, Nazanin Saedi, Kavita Mariwalla, Terrence Keaney, and Thomas Rohrer.

This video series and podcast are supported in part by Alastin Skincare, Endo Aesthetics, Ortho Dermatologics, and Sciton.

We hope these pearls and best practices help with safely reopening your practice!

Watch the companion videos here:
https://jddonline.com/reopening-derm-practices

Read the full Project AesCert Guidance in the July eJDD here:

Systemic Antibiotics in the Management of Acne: Issues and Considerations for Optimal Care

By Podcast
WEEEEEEERE BACK! Join host Dr. Adam Friedman for lively and learned discussion with Dr. Joslyn Kirby on one of the most common, chronic, soul-crushing complaints… Acne Vulgaris. It is, from a pathophysiological standpoint, a biological sh*t show, but you need to understand it to develop the best treatment plans. We talk inflammation, first line approaches, setting patient expectations and compliance. We dive deep into the differences between broad-spectrum and narrow-spectrum antibiotics, when to use them, and for how long. (Spoiler alert: NOT TOO LONG!). In our efforts to be stewards of meaningful antibiotic use and adversaries of antimicrobial resistance, narrow-spectrum antibiotics are the future!
This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.
Upon completion of this enduring, internet-based educational activity, participants should be able to:
  • Review current scientific understanding of pathophysiology of acne
  • Summarize acne treatment strategies utilizing systemic antibiotics
  • Differentiate safety and efficacy of broad and narrow spectrum antibiotics indicated for acne treatment
  • Cite the benefits of narrow spectrum antibiotic use in acne therapy
Disclosures:
Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speaker’s Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
Joslyn R. Sciacca Kirby, MD – No relevant disclosures.